Asset
ATALUREN
PTC THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (28)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04117880 | phase2 | withdrawn | 2018-12-31 | 2021-01-31 | PTC Therapeutics | A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia |
| NCT00458341 | phase2 | completed | 2007-03-23 | 2008-02-29 | PTC Therapeutics | A Study of Ataluren in Pediatric Participants With Cystic Fibrosis |
| NCT03648827 | phase2 | completed | 2018-12-21 | 2020-10-23 | PTC Therapeutics | A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) |
| NCT03796637 | phase2 | completed | 2019-04-11 | 2019-06-03 | PTC Therapeutics | A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren |
| NCT04336826 | phase2 | completed | 2021-12-29 | 2023-08-07 | PTC Therapeutics | A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) |
FDA applications (0)
This company has no applications containing this asset.